DK2374468T3 - Anvendelse af peptid af APL-typen til behandling af inflammatoriske tarmsygdomme og type 1-diabetes - Google Patents

Anvendelse af peptid af APL-typen til behandling af inflammatoriske tarmsygdomme og type 1-diabetes

Info

Publication number
DK2374468T3
DK2374468T3 DK09804226.0T DK09804226T DK2374468T3 DK 2374468 T3 DK2374468 T3 DK 2374468T3 DK 09804226 T DK09804226 T DK 09804226T DK 2374468 T3 DK2374468 T3 DK 2374468T3
Authority
DK
Denmark
Prior art keywords
type
peptide
apl
diabetes
inflammatory bowel
Prior art date
Application number
DK09804226.0T
Other languages
English (en)
Inventor
Betancourt Ariana Barbera
Nguez Horta Mara A Del Carmen Doma
Palomares Gabriel Ramon Padron
Cama Viviana Falcon
Valdes Ivon Menendez
Perez Norailys Lorenzo
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Application granted granted Critical
Publication of DK2374468T3 publication Critical patent/DK2374468T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/03Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
DK09804226.0T 2008-12-29 2009-12-29 Anvendelse af peptid af APL-typen til behandling af inflammatoriske tarmsygdomme og type 1-diabetes DK2374468T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20080254A CU23701A1 (es) 2008-12-29 2008-12-29 Método de tratamiento de enfermedades inflamatorias intestinales y diabetes tipo i
PCT/CU2009/000009 WO2010075824A1 (es) 2008-12-29 2009-12-29 Uso de peptido tipo apl para el tratamiento de enfermedades inflamatorias intestinales y diabetes tipo i

Publications (1)

Publication Number Publication Date
DK2374468T3 true DK2374468T3 (da) 2013-12-09

Family

ID=41820665

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09804226.0T DK2374468T3 (da) 2008-12-29 2009-12-29 Anvendelse af peptid af APL-typen til behandling af inflammatoriske tarmsygdomme og type 1-diabetes

Country Status (15)

Country Link
US (1) US8410057B2 (da)
EP (1) EP2374468B1 (da)
JP (1) JP5646506B2 (da)
KR (1) KR101620341B1 (da)
CN (1) CN102307587B (da)
AU (1) AU2009335405B2 (da)
BR (1) BRPI0923832B1 (da)
CA (1) CA2748493C (da)
CU (1) CU23701A1 (da)
DK (1) DK2374468T3 (da)
ES (1) ES2438096T3 (da)
MX (1) MX2011007033A (da)
RU (1) RU2524630C2 (da)
WO (1) WO2010075824A1 (da)
ZA (1) ZA201105320B (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109562137A (zh) 2015-09-01 2019-04-02 第波生物公司 用于治疗与异常炎性反应有关的病况的方法和组合物
CU24508B1 (es) 2017-12-29 2021-04-07 Centro De Ingenieria Genetica Y Biotecnologia Biocubafarma Composición farmacéutica que comprende péptido tipo apl
US10980756B1 (en) 2020-03-16 2021-04-20 First Wave Bio, Inc. Methods of treatment
CU20200026A7 (es) * 2020-04-13 2021-11-04 Ct Ingenieria Genetica Biotecnologia Péptido para el tratamiento del síndrome de la tormenta de citocinas
CN115671253B (zh) * 2021-07-30 2024-02-27 河北菲尼斯生物技术有限公司 Se-dr亲和肽在制备治疗风湿疾病的药物中的用途
KR20250040663A (ko) * 2022-07-22 2025-03-24 센트로 데 인제니에리아 제네티카 와이 바이오테크놀로지아 아포지질단백질 ai 또는 트랜스티레틴 내 문제와 연관된 질병을 치료하기 위한 펩타이드

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8003A (en) * 1851-03-25 Improvement in scythe-tastenings
RO116777B1 (ro) * 1994-12-21 2001-06-29 Yeda Res & Dev Analog de peptida p277, compozitie farmaceutica si metoda pentru diagnosticarea diabetului mellitus insulino-dependent, cu acesta
US6180103B1 (en) * 1994-12-21 2001-01-30 Yeda Research And Development Co., Ltd. Peptide p277 analogs, and pharmaceutical compositions comprising them for treatment or diagnosis of diabetes
IL114407A0 (en) 1995-06-30 1995-10-31 Yeda Res & Dev Novel peptides and pharmaceutical compositions comprising them
US6110746A (en) * 1995-06-30 2000-08-29 Yeda Research And Development Co. Ltd. Peptides derived from human heat shock protein 60 for treatment of diabetes, compositions, methods and kits
CA2394504A1 (en) * 1999-12-15 2001-06-21 Peptor Ltd. Fragments and antagonists of heat shock protein 60
CA2547079A1 (en) * 2003-11-24 2005-06-02 Yeda Research & Development Co. Ltd. Dna vaccines encoding hsp60 peptide fragments for treating autoimmune diseases
CU23504A1 (es) * 2004-09-24 2010-04-13 Ct Ingenieria Genetica Biotech Péptidos y derivados tipo apl de la hsp60 y composiciones farmacéuticas

Also Published As

Publication number Publication date
MX2011007033A (es) 2011-07-20
JP5646506B2 (ja) 2014-12-24
WO2010075824A1 (es) 2010-07-08
BRPI0923832A2 (pt) 2015-07-21
EP2374468B1 (en) 2013-09-11
ES2438096T3 (es) 2014-01-15
RU2011131872A (ru) 2013-02-10
KR20110119677A (ko) 2011-11-02
AU2009335405B2 (en) 2013-07-18
US20120035106A1 (en) 2012-02-09
ZA201105320B (en) 2012-04-25
AU2009335405A1 (en) 2011-08-25
CN102307587B (zh) 2014-04-30
JP2012514013A (ja) 2012-06-21
CN102307587A (zh) 2012-01-04
CU23701A1 (es) 2011-09-21
CA2748493A1 (en) 2010-07-08
KR101620341B1 (ko) 2016-05-12
BRPI0923832B1 (pt) 2019-09-24
US8410057B2 (en) 2013-04-02
RU2524630C2 (ru) 2014-07-27
EP2374468A1 (en) 2011-10-12
CA2748493C (en) 2017-08-22

Similar Documents

Publication Publication Date Title
EA201100621A1 (ru) Лечение диабета у пациентов, у которых наблюдается недостаточный гликемический контроль несмотря на лечение пероральным или непероральным противодиабетическим лекарственным средством
DK2374468T3 (da) Anvendelse af peptid af APL-typen til behandling af inflammatoriske tarmsygdomme og type 1-diabetes
EA201170149A1 (ru) Новые аналоги инсулина пролонгированной активности
EA201171451A1 (ru) Генетические маркеры, ассоциированные с ответом на интерферон-альфа
CY1117869T1 (el) Φαρμακοτεχνικες μορφες για απο του στοματος απελευθερωση προσροφητικων στο εντερο
EA200971130A1 (ru) Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний
NZ607189A (en) Materials and methods for improving gastrointestinal function
EA201891510A1 (ru) Вазопротективное и кардиопротективное противодиабетическое лечение
MX336412B (es) Nuevos analogos de glucagon.
MX2011007397A (es) Inhibidores de dpp-iv para el tratamiento de la diabetes en pacientes pediatricos.
EA201300522A1 (ru) Фармацевтические комбинации для лечения метаболических нарушений
MY157564A (en) Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract
LT2013018A (lt) Farmacinė kompozicija, skirta gydyti diabetą ir metabolinius sutrikimus
ATE525070T1 (de) Silbininkomponente zur behandlung von hepatitis
WO2006063093A3 (en) Methods for diagnosis and treatment of crohn's disease
DK1915620T3 (da) Diagnose, behandling og prævention af vaskulære sygdomme ved hjælp af IL-1alpha-autoantistoffer
EA201792030A1 (ru) Лечение пациентов с сахарным диабетом 2 типа
MX2015000016A (es) Proteinas protozoarias variables de superficie (vsp) como vehiculos para la administracion de farmacos.
CY1119308T1 (el) Συνδυασμοι με ενα πεπτιδιο κυκλοποιημενου σκελετου
WO2009046875A3 (en) Combination of splenopentin and thymopentin and the use thereof in medicine
DK2096120T3 (da) Anvendelse af sekreterede proteinprodukter til at forebygge og behandle pankreatiske sygdomme og/eller obesitet og/eller metabolsk syndrom
Safatle-Ribeiro et al. Hemorrhagic gastritis at the excluded stomach after Roux-en-Y gastric bypass
TH93866B (th) องค์ประกอบที่มีกรดโดโคซาเพนทาอีโนอิค
TH93866A (th) องค์ประกอบที่มีกรดโดโคซาเพนทาอีโนอิค
Chondronikola et al. You have free access to this contentBariatric surgery and type 2 diabetes: are there weight loss-independent therapeutic effects of upper gastrointestinal bypass?